← Eichor
Condition: Neurofibromatosis Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Neurofibromatosis

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Mirdametinib in Patients With Advanced NF1-mutant Melanoma
Phase 2 · 1 location(s) · Kevin Kim, MD · NCT07237100A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Phase 3 · 132 location(s) · National Cancer Institute (NCI) · NCT04166409Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders
Phase N/A · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT06147414Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Glioma
EARLY_Phase 1 · 1 location(s) · Daniel Morgenstern · NCT06381570A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
Phase 1/Phase 2 · 19 location(s) · Therapeutic Advances in Childhood Leukemia Consortium · NCT05849662Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform
Phase 3 · 29 location(s) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · NCT07407803Tailoring an Online Platform to Promote Evidence-Based Care for Adults With Neurofibromatosis 1 and Low Health Literacy
NA · 1 location(s) · Massachusetts General Hospital · NCT07233408Cutaneous and Mucosal Manifestations of Neurofribromatosis Type 2 in Children Under 15
Phase N/A · 1 location(s) · Centre Hospitalier Universitaire de Nice · NCT03893643PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas
Phase 1 · 5 location(s) · Pasithea Therapeutics Corp. · NCT06961565FARD (RaDiCo Cohort) (RaDiCo-FARD)
Phase N/A · 15 location(s) · Institut National de la Santé Et de la Recherche Médicale, F · NCT05954416Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Phase 1 · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT03454035DoD Award NF230020 Identification of Metabolic Markers and Statistical Prediction of MPNST for Rapid Diagnosis and Asses
Phase N/A · 1 location(s) · M.D. Anderson Cancer Center · NCT07298083HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
Phase 2 · 1 location(s) · Shanghai Kechow Pharma, Inc. · NCT05331105Familial Investigations of Childhood Cancer Predisposition
Phase N/A · 1 location(s) · St. Jude Children's Research Hospital · NCT03050268A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1
Phase 2 · 14 location(s) · Healx Limited · NCT06541847Prevalence, Clinical Characteristics, Progression, and Management of Neurofibromatosis Type 1 in Egypt (NF1-Egy)
Phase N/A · 9 location(s) · AstraZeneca · NCT07221331Evaluation of Percutaneous Cryotherapy in the Treatment of Plexiform Neurofibromas and Unresectable Neurofibromas in Neu
NA · 1 location(s) · Centre Leon Berard · NCT05199376A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Maligna
EARLY_Phase 1 · 1 location(s) · University of Minnesota · NCT06693284Natural History Study of Patients With Neurofibromatosis Type 2
Phase N/A · 1 location(s) · National Institute of Neurological Disorders and Stroke (NIN · NCT00598351Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1
Phase 1 · 1 location(s) · Johns Hopkins University · NCT07102394Immunotherapy Based on Antigen-specific Immune Effector Cells Targeting Neurofibromatosis or Schwannomatosis
Phase 1/Phase 2 · 1 location(s) · Shenzhen Geno-Immune Medical Institute · NCT04085159Real-World Treatment Study of Koselugo (Selumetinib)
Phase N/A · 12 location(s) · AstraZeneca · NCT06360406Phase 1/2 Study of Mirdametinib + Vinblastine for Newly Diagnosed/Previously Untreated PLGG + Activation of MAPK
Phase 1/Phase 2 · 8 location(s) · St. Justine's Hospital · NCT06666348Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractor
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT02390752Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients
Phase N/A · 3 location(s) · Universidad Nacional Autonoma de Mexico · NCT06523582MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT05735717Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
Phase 2 · 6 location(s) · Scott R. Plotkin, MD, PhD · NCT04374305Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST
Phase 1/Phase 2 · 2 location(s) · AeRang Kim · NCT06735820Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and F
NA · 1 location(s) · National Cancer Institute (NCI) · NCT05361811Glioma Developmental and HyperActive Ras Tumor (DHART) Board
Phase N/A · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT05489783
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.